Harvard Bioscience
HBIO
HBIO
91 hedge funds and large institutions have $14.5M invested in Harvard Bioscience in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 37 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less ownership
Funds ownership: →
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
41% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 37
78% less capital invested
Capital invested by funds: $65.5M → $14.5M (-$51M)
Holders
91
Holding in Top 10
1
Calls
$5K
Puts
$4K
Top Buyers
| 1 | +$502K | |
| 2 | +$148K | |
| 3 | +$102K | |
| 4 |
Renaissance Technologies
New York
|
+$98.4K |
| 5 |
Squarepoint
New York
|
+$96.3K |
Top Sellers
| 1 | -$2.85M | |
| 2 | -$2.43M | |
| 3 | -$1.55M | |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$422K |
| 5 |
HP
Harvey Partners
Tarrytown,
New York
|
-$280K |